Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide

We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Sean, Gabriel, Nico, Hernandez, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698192/
https://www.ncbi.nlm.nih.gov/pubmed/36205353
http://dx.doi.org/10.1097/QAD.0000000000003401
_version_ 1784838755406839808
author Dickson, Sean
Gabriel, Nico
Hernandez, Inmaculada
author_facet Dickson, Sean
Gabriel, Nico
Hernandez, Inmaculada
author_sort Dickson, Sean
collection PubMed
description We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild.
format Online
Article
Text
id pubmed-9698192
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96981922022-11-28 Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide Dickson, Sean Gabriel, Nico Hernandez, Inmaculada AIDS Research Letter We estimated list and net prices for tenofovir disoproxil fumarate (TDF) products Truvada, Complera, and Stribild, and their tenofovir alafenamide (TAF) versions Descovy, Odefsey, and Genvoya. Gilead offered discounts for Descovy that resulted into lower net prices compared to Truvada. This strategy encouraged patients switching from Truvada to Descovy before the availability of generic Truvada. Conversely, Gilead offered lower discounts for Odefsey and Genvoya, which resulted into higher net prices compared to Complera and Stribild. Lippincott Williams & Wilkins 2022-12-01 2022-10-06 /pmc/articles/PMC9698192/ /pubmed/36205353 http://dx.doi.org/10.1097/QAD.0000000000003401 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Research Letter
Dickson, Sean
Gabriel, Nico
Hernandez, Inmaculada
Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title_full Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title_fullStr Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title_full_unstemmed Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title_short Estimated changes in price discounts for tenofovir-inclusive HIV treatments following introduction of tenofovir alafenamide
title_sort estimated changes in price discounts for tenofovir-inclusive hiv treatments following introduction of tenofovir alafenamide
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698192/
https://www.ncbi.nlm.nih.gov/pubmed/36205353
http://dx.doi.org/10.1097/QAD.0000000000003401
work_keys_str_mv AT dicksonsean estimatedchangesinpricediscountsfortenofovirinclusivehivtreatmentsfollowingintroductionoftenofoviralafenamide
AT gabrielnico estimatedchangesinpricediscountsfortenofovirinclusivehivtreatmentsfollowingintroductionoftenofoviralafenamide
AT hernandezinmaculada estimatedchangesinpricediscountsfortenofovirinclusivehivtreatmentsfollowingintroductionoftenofoviralafenamide

Ejemplares similares